To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
-
Parkin/PINK1 Double KO Rat
Breeding of the CRISPR Parkin KO Sprague Dawley rat with the CRISPR PINK1 KO Sprague Dawley rat to create a line with homozygous deletion of both genes.
Estimated Availability: Mid 2026
-
PINK1 KO Rat
CRISPR/Cas9 genome targeting strategy to knockout PINK1 on a Sprague Dawley rat background.
Estimated Availability: Late 2025
-
Parkin KO Rat
CRISPR/Cas9 genome targeting strategy to knockout Parkin on a Sprague Dawley rat background.
Estimated Availability: Late 2025
-
LRRK2 KO Rat
CRISPR/Cas9 genome targeting strategy to knockout LRRK2 on a Sprague Dawley rat background.
Estimated Availability: Early 2026
-
Rab 12 Antibody (IP)
Rabbit monoclonal antibody directed against human Rab 12. Suitable for use in immunoprecipitation.
-
Rab 10 Protein
Rab10 semi-synthetic phosphomimetic protein fragment (AA66-181) generated by native chemical ligation of recombinant peptides. To be used as a control with the pT73 Rab1o protein.
-
Floxed S69R Rab32 Mouse
Mouse expressing the S69R point mutation in the mouse Rab32 gene (corresponds to the S71R mutation in human Rab32). LoxP sites flank the Rab32 gene to enable conditional Cre-mediated knockout.
Estimated Availability: Early 2026
-
S69R Rab32 KI Mouse
CRISPR/Cas9 genome targeting strategy to knockin S69R point mutation in the endogenous mouse Rab32 gene (corresponds to the S71R mutation in human Rab32).
Estimated Availability: Early 2025
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic